Cited by 223Lipoproteins and Cardiovascular HealthCardiovascular Health and Disease PreventionAtherosclerosis and Cardiovascular Diseases

The DOI matches its Crossref record, with a small difference in title or year; 14 of the 14 references it cites were found in a registry or an index.

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

Open access

Villines, Todd C., Stanek, Eric J., Devine, Patrick J., Turco, Mark, Miller, Michael, Weissman, Neil J., Griffen, Len, Taylor, Allen J.·2010·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2010.03.017

Open this paper in CoChat — free account Open PDF

Abstract

Objectives This report describes the final results of the ARBITER 6-HALTS (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) trial.Background The ARBITER 6-HALTS trial was terminated early on the basis of a pre-specified interim analysis showing superiority of niacin over ezetimibe on change in carotid intima-media thickness (CIMT). After termination, an additional 107 subjects completed a close-out assessment.Methods Patients with coronary heart disease (CHD) or CHD equivalent with low-density lipoprotein cholesterol <100 mg/dl and high-density lipoprotein cholesterol <50 mg/dl for men or 55 mg/dl for women while receiving stable statin treatment were randomly assigned to ezetimibe (10 mg/day) or extended-release niacin (target dose, 2,000 mg/day). The primary end point was change in mean CIMT, analyzed according to a last observation carried forward method. The relationships of study medication adherence, dosage, and cumulative exposure (product of adherence, dose, and time) with change in CIMT were explored.Results Results in 315 patients included 208 with 14-month follow-up and 107 after mean treatment of 7 +/- 3 months. Niacin (n = 154) resulted in significant reduction (regression) in mean CIMT (-0.0102 +/- 0.0026 mm; p < 0.001) and maximal CIMT (-0.0124 +/- 0.0036 mm; p = 0.001), whereas ezetimibe (n = 161) did not reduce mean CIMT (-0.0016 +/- 0.0024 mm; p = 0.88) or maximal CIMT (-0.0005 +/- 0.0029 mm; p = 0.88) compared with baseline. There was a significant difference between ezetimibe and niacin treatment groups on mean changes in CIMT, favoring niacin, for both mean CIMT (p = 0.016) and maximal CIMT (p = 0.01). Increased cumulative drug exposure was related to regression of CIMT with niacin, and progression of CIMT with ezetimibe.Conclusions Niacin induces regression of CIMT and is superior to ezetimibe for patients taking statins. (Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis; NCT00397657).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2010.03.017

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events
Hodis, H. N., Mack, W. J., LaBree, L., Selzer, R. H., Liu, C.-R., Liu, C.-H., & Azen, S. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-4-199802150-00002 · Cited by 1,217
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 888
Self-citation
Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis
Crouse, J. R., Raichlen, J. S., Riley, W. A., Evans, G. W., Palmer, M. K., O’Leary, D. H., Grobbee, D. E., Bots, M. L., & for the METEOR Study Group (2007) · JAMA · doi:10.1001/jama.297.12.1344 · Cited by 708
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M. J., Weissman, N. J., & Turco, M. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 638
Self-citation
The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3
Taylor, A. J., Lee, H. J., & Sullenberger, L. E. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148508 · Cited by 303
Self-citation

Show all 14 references

Sorted by citations

ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
NAD+ homeostasis in health and disease
Katsyuba, E., Romani, M., Hofer, D., & Auwerx, J. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0161-5 · Cited by 627
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk
Willeit, P., Tschiderer, L., Allara, E., Reuber, K., Seekircher, L., Gao, L., Liao, X., Lonn, E., Gerstein, H. C., Yusuf, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046361 · Cited by 476
Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 440
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336
Self-citation
Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 307
High-Density Lipoprotein
Lüscher, T. F., Landmesser, U., von Eckardstein, A., & Fogelman, A. M. (2014) · Circulation Research · doi:10.1161/circresaha.114.300935 · Cited by 299
Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013) · Drugs · doi:10.1007/s40265-013-0023-5 · Cited by 308
Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
Lukasova, M., Malaval, C., Gille, A., Kero, J. T., & Offermanns, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci41651 · Cited by 269
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects
Toma, I., & McCaffrey, T. A. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1189-3 · Cited by 193
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
Cardiovascular drug therapy in the elderly: benefits and challenges
Fleg, J. L., Aronow, W. S., & Frishman, W. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.162 · Cited by 186
The Current State of Niacin in Cardiovascular Disease Prevention
Lavigne, P. M., & Karas, R. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.030 · Cited by 185
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial
Aim-High Investigators (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.007 · Cited by 174
Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists
Fitridge, R., & Thompson, M. M. (2011) · Cited by 168
Novel HDL-directed pharmacotherapeutic strategies
deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149
Interaction between high-density lipoproteins and inflammation: function matters more than concentration!
Nazir, S., Jankowski, V., Bender, G., Zewinger, S., Rye, K.-A., & van der Vorst, E. P. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.006 · Cited by 140
Niacin for primary and secondary prevention of cardiovascular events
Schandelmaier, S., Briel, M., Saccilotto, R. T., Olu, K. K., Arpagaus, A., Hemkens, L. G., & Nordmann, A. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009744.pub2 · Cited by 120
American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: Executive Summary
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., Seibel, J. A., Kreisberg, R. A., & Goldberg, R. B. (2012) · Endocrine Practice · doi:10.4158/ep.18.2.269 · Cited by 113
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events
Zhan, S., Tang, M., Liu, F., Xia, P., Shu, M., & Wu, X. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012502.pub2 · Cited by 109
The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease
Brewer, H. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0163 · Cited by 96
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
Blazing, M. A., Giugliano, R. P., Cannon, C. P., Musliner, T. A., Tershakovec, A. M., White, J. A., Reist, C., McCagg, A., Braunwald, E., & Califf, R. M. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.05.004 · Cited by 96
Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
GPR109A and Vascular Inflammation
Chai, J. T., Digby, J. E., & Choudhury, R. P. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0325-9 · Cited by 78
Niacin: an old lipid drug in a new NAD+ dress
Romani, M., Hofer, D., Katsyuba, E., & Auwerx, J. H. (2019) · Journal of Lipid Research · doi:10.1194/jlr.s092007 · Cited by 72
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol
The AIM-HIGH Investigators (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.11.017 · Cited by 72
Biological and Pharmacological Roles of HCA Receptors
Blad, C. C., Ahmed, K., IJzerman, A. P., & Offermanns, S. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385952-5.00005-1 · Cited by 73
Niacin and Statin Combination Therapy for Atherosclerosis Regression and Prevention of Cardiovascular Disease Events
Michos, E. D., Sibley, C. T., Baer, J., Blaha, M. J., & Blumenthal, R. S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.045 · Cited by 68
Drug-related hypertension and resistance to antihypertensive treatment
Rossi, G. P., Seccia, T. M., Maniero, C., & Pessina, A. C. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834c465d · Cited by 68
Atherosclerosis: lessons from LXR and the intestine
Bonamassa, B., & Moschetta, A. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.10.004 · Cited by 67
The Therapeutic Role of Niacin in Dyslipidemia Management
Boden, W. E., Sidhu, M. S., & Toth, P. P. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413514481 · Cited by 69
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 64
How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol
Lim, S. K., Park, Y. M., Sakuma, I., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.127 · Cited by 64
Cardiovascular implications of HIV-induced dyslipidemia
Giannarelli, C., Klein, R. S., & Badimón, J. J. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.003 · Cited by 65
“In vivo” imaging of atherosclerosis
Gallino, A., Stuber, M., Crea, F., Falk, E., Corti, R., Lekakis, J. P., Schwitter, J., Camici, P. G., Gaemperli, O., Valentino, M. D., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.04.007 · Cited by 67
Niacin in Cardiovascular Disease: Recent Preclinical and Clinical Developments
Digby, J. E., Ruparelia, N., & Choudhury, R. P. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.236315 · Cited by 53
Combination therapy in dyslipidemia: Where are we now?
Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.026 · Cited by 52
Lifestyle Changes: Effect of Diet, Exercise, Functional Food, and Obesity Treatment on Lipids and Lipoproteins
Enkhmaa, B., Surampudi, P. N., Anuurad, E., & Berglund, L. (2015) · Europe PMC (PubMed Central) · Cited by 50
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Hamilton-Craig (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s13496 · Cited by 48
Niacin: The Evidence, Clinical Use, and Future Directions
Villines, T. C., Kim, A. S., Gore, R. S., & Taylor, A. J. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0212-1 · Cited by 48
Self-citation
Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?
Mani, P., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0521-x · Cited by 47
Recent Clinical Studies of the Effects of Lipid-Modifying Therapies
Gotto, A. M., & Moon, J. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.003 · Cited by 44
The prevention and regression of atherosclerotic plaques: emerging treatments
Ling, G. S. F., Kalanuria, & Nyquist (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s27764 · Cited by 45
Ezetimibe Therapy for Dyslipidemia: An Update
Katsiki, N., Theocharidou, E., Karagiannis, A. I., Athyros, V. G., & Mikhailidis, D. P. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990314 · Cited by 43
Atherosclerosis: Making a U Turn
Goldberg, I. J., Sharma, G. K., & Fisher, E. A. A. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-042418-011108 · Cited by 44
Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
Shearer, G. C., Pottala, J. V., Hansen, S. N., Brandenburg, V., & Harris, W. S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p022392 · Cited by 42
Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe
Taylor, A. J., Villines, T. C., & Stanek, E. J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs105 · Cited by 40
Self-citation
Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus
Winkler, K., Jacob, S., Schewe, T., Hoffmann, M. M., & Konrad, T. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.043 · Cited by 39
Effect of niacin on endothelial function: A systematic review and meta-analysis of randomized controlled trials
Sahebkar, A. (2014) · Vascular Medicine · doi:10.1177/1358863x13515766 · Cited by 41
Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?
Halcox, J., & Misra, A. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0049 · Cited by 38
Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy
Hippe, D. S., Phan, B. A. P., Sun, J., Isquith, D. A., O’Brien, K. D., Crouse, J. R., Anderson, T. J., Huston, J., Marcovina, S. M., Hatsukami, T. S., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310368 · Cited by 40
Implications of reverse cholesterol transport: Recent studies
Levinson, S. S., & Wagner, S. G. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.018 · Cited by 36
Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure
Walker, J. J., Johnson, J. A., & Wild, S. H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70028-7 · Cited by 37
Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization
Shi, Y., Lai, X., Ye, L., Chen, K., Cao, Z., Gong, W., Jin, L., Wang, C., Liu, M., Liao, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep42279 · Cited by 38
Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Battaggia, A., Donzelli, A., Font, M., Molteni, D., & Galvano, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124587 · Cited by 36
A practical approach to the metabolic syndrome: review of current concepts and management
Tota-Maharaj, R., DeFilippis, A. P., Blumenthal, R. S., & Blaha, M. J. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32833cd474 · Cited by 35
Effects of niacin on atherosclerosis and vascular function
Ruparelia, N., Digby, J. E., & Choudhury, R. P. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283410c16 · Cited by 35
CKD, Plasma Lipids, and Common Carotid Intima-Media Thickness
Lamprea-Montealegre, J. A., Astor, B. C., McClelland, R. L., de Boer, I. H., Burke, G. L., Sibley, C. T., O’Leary, D. H., Sharrett, A. R., & Szklo, M. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02090212 · Cited by 34
Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy
Ito, M. K. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r127 · Cited by 34
High Density Lipoprotein: A Therapeutic Target in Type 2 Diabetes
Barter, P. J. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.3.169 · Cited by 33
Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress
Kostapanos, M. S., Spyrou, A., Tellis, C. C., Gazi, I. F., Tselepis, A. D., Elisaf, M., & Liberopoulos, E. N. (2011) · Lipids · doi:10.1007/s11745-011-3539-z · Cited by 32
Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?
Larach, D. B., deGoma, E. M., & Rader, D. J. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0317-3 · Cited by 33
NAD+ Metabolism as an Emerging Therapeutic Target for Cardiovascular Diseases Associated With Sudden Cardiac Death
Xu, W., Li, L., & Zhang, L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00901 · Cited by 35
A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs
Alla, V. M., Agrawal, V., DeNazareth, A., Mohiuddin, S., Ravilla, S., & Rendell, M. (2013) · Drugs · doi:10.1007/s40265-013-0072-9 · Cited by 33
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)
Brunner, G., Yang, E. Y., Kumar, A., Sun, W., Virani, S. S., Negi, S., Murray, T. O., Lin, P. H., Hoogeveen, R. C., Chen, C., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.034 · Cited by 30
Self-citation
Current guidelines for high-density lipoprotein cholesterol in therapy and future directions
Michos, E. D., Subedi, B. H., Joshi, P. H., Jones, S. R., Martin, S. S., & Blaha, M. J. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s45648 · Cited by 31
Therapeutic strategies to deplete macrophages in atherosclerotic plaques
Meyer, I. D., Martinet, W., & Meyer, G. R. Y. D. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04211.x · Cited by 31
Niacin: the only vitamin that reduces cardiovascular events
Wierzbicki, A. S. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02630.x · Cited by 28
Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?
Hermans, M. P., & Fruchart, J. (2010) · Clinical Lipidology · doi:10.2217/clp.10.65 · Cited by 28
Carotid Intima-Media Thickness Testing as an Asymptomatic Cardiovascular Disease Identifier and Method for Making Therapeutic Decisions
Doneen, A. L., & Bale, B. F. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.03.2645 · Cited by 28
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy
Toth, P. P. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s22601 · Cited by 27
The Efficacy and Safety of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors in Chronic Kidney Disease, Dialysis, and Transplant Patients
Olyaei, A. J., Greer, E., Santos, R. D., & Rueda, J. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09091010 · Cited by 27
Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases
Giammanco, A., Noto, D., Barbagallo, C. M., Nardi, E., Caldarella, R., Ciaccio, M., Averna, M. R., & Cefalu, A. B. (2021) · Life · doi:10.3390/life11060581 · Cited by 27
Nicotinic Acid Receptor GPR109A Is Down-Regulated in Human Macrophage-Derived Foam Cells
Chai, J. T., Digby, J. E., Ruparelia, N., Jefferson, A., Handa, A. I., & Choudhury, R. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062934 · Cited by 27
Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease
Maki, K. C., Davidson, M. H., Dicklin, M. R., Bell, M., Witchger, M., & Feinstein, S. B. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.02.003 · Cited by 26
High-density lipoprotein levels and risk of cardiovascular events
Mureddu, G. F., Brandimarte, F., & Luca, L. D. (2011) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32834bb3c8 · Cited by 26
The effects of nicotinamide adenine dinucleotide in cardiovascular diseases: Molecular mechanisms, roles and therapeutic potential
Zhang, X., Zhang, Y., Sun, A., & Ge, J. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.04.001 · Cited by 24
Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics
Goel, H., & Dunbar, R. L. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0570-9 · Cited by 23
Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010
Ross, J. S., Frazee, S. G., Garavaglia, S. B., Levin, R., Novshadian, H., Jackevicius, C. A., Stettin, G., & Krumholz, H. M. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3404 · Cited by 22
High-density lipoprotein cholesterol raising
Schofield, J. D., France, M. W., Ammori, B. J., Liu, Y., & Soran, H. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328362210d · Cited by 24
Nicotinic acid: clinical considerations
Kei, A. A., & Elisaf, M. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.682981 · Cited by 21
HDL Cholesterol and Cardiovascular Outcomes: What Is the Evidence?
Rubenfire, M., & Brook, R. D. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0349-3 · Cited by 22
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
Blazing, M. A., Giugliano, R. P., de Lemos, J. A., Cannon, C. P., Tonkin, A. M., Ballantyne, C. M., Lewis, B. S., Musliner, T. A., Tershakovec, A. M., Lokhnygina, Y. V., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.004 · Cited by 21
Pharmacologic Use of Niacin
Prousky, J. E., Millman, C. G., & Kirkland, J. B. (2011) · Journal of Evidence-Based Complementary & Alternative Medicine · doi:10.1177/2156587211399579 · Cited by 21
Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis
Miura, Y., & Suzuki, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416224 · Cited by 21
Prospective observation on the association of snoring with subclinical changes in carotid atherosclerosis over four years
Kim, J., Pack, A. I., Maislin, G., Lee, S. K., Kim, S. H., & Shin, C. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.03.009 · Cited by 19
Optimal pharmacotherapy to combat the atherogenic lipid triad
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32834965e9 · Cited by 18
Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction
Bregar, U., Jug, B., Keber, I., Cevc, M., & Šebeštjen, M. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0367-5 · Cited by 18
‘Trig-onometry’: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia
Jacobson, T. A. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02547.x · Cited by 17
New evidence for nicotinic acid treatment to reduce atherosclerosis
Montecucco, F., Quercioli, A., Dallegri, F., Viviani, G. L., & Mach, F. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.116 · Cited by 17
Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada
Lu, L., Krumholz, H. M., Tu, J. V., Ross, J. S., Ko, D. T., & Jackevicius, C. A. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.01.014 · Cited by 16
Effect of comprehensive cardiovascular disease risk management on longitudinal changes in carotid artery intima-media thickness in a community-based prevention clinic
Cheng, H. G., Patel, B., Martin, S. S., Blaha, M. J., Doneen, A. L., Bale, B. F., & Jones, S. R. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.60955 · Cited by 16
High-density lipoprotein cholesterol: How High
Sachan, A., Rajagopal, G. M., & Suresh, V. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.104048 · Cited by 18
Managing dyslipidaemia in type 2 diabetes mellitus
Szalat, A., Durst, R. Y., & Leitersdorf, E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.05.004 · Cited by 17
Xuezhitong capsule, an extract of Allium macrostemon Bunge, exhibits reverse cholesterol transport and accompanies high-density lipoprotein levels to protect against hyperlipidemia in ApoE−/− mice
Meng, X., Zhu, T., Yang, D., Liang, W., Sun, G., & Sun, X. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.77 · Cited by 15

Authors: Villines, T. C., Stanek, E. J., Devine, P. J., Turco, M., Miller, M., Weissman, N. J., Griffen, L., & Taylor, A. J.
Affiliations: Walter Reed National Military Medical Center (US)
Washington Adventist Hospital (US)
University of Maryland Medical Center (US)
MedStar Washington Hospital Center (US)
Corresponding author: Villines, Todd C.
ORCID: Villines, Todd C.
Miller, Michael
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2010-06
Volume: 55
Issue: 24
Pages: 2721-2726
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2010.03.017
OpenAlex: W2187593761
Cited by: 223
References: 14
Citations by year: 2026: 1 · 2025: 2 · 2024: 5 · 2022: 2 · 2021: 5 · 2020: 10 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 12 · 2015: 11 · 2014: 20 · 2013: 33 · 2012: 40
FWCI: 46.84
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1141 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: Henry M. Jackson Foundation
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords: nicotinic acid, ezetimibe, carotid intima-media thickness, atherosclerosis, coronary artery disease, statin-treated patients, LDL cholesterol, HDL cholesterol, medication adherence, cumulative drug exposure, atherosclerosis regression, lipid-lowering therapy, trial termination, cardiovascular risk reduction, statin-sparing therapy
MeSH terms: Ezetimibe, Aged, Anticholesteremic Agents, Azetidines, Coronary Disease, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Niacin, Time Factors, Ultrasonography, Single-Blind Method, Treatment Outcome, Carotid Artery, Common, Tunica Intima, Atherosclerosis, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks